Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Mesenchymal stromal cells (MSCs) are often described as the body’s natural repair system - remarkable cells capable of calming inflammation, modulating immune responses and regenerating damaged tissue. For decades, scientists have seen them as the foundation for an entirely new class of regenerative medicine. Yet one challenge has always stood in the way of allowing MSCs to realise their full potential: how to make enough of them, consistently, to treat patients at scale.

 Melbourne-based Cynata Therapeutics (ASX: CYP) has got a solution for that problem. Its Cymerus™ platform can produce an essentially limitless supply of consistent, potent MSCs from a single blood donation - a breakthrough that could redefine how cell therapies are manufactured and delivered.

Image: Cynata’s iPSC-MSCs

The company is now approaching the most important period in its history - with two landmark clinical trial readouts fast approaching in osteoarthritis and acute graft-versus-host disease (aGvHD). And unlike most companies heading into late-stage data, Cynata does so with a powerful advantage - it already has proven in-human efficacy from earlier clinical trials.

 “We’ve already shown our Cymerus™ MSCs can deliver meaningful efficacy and survival benefits in patients with life-threatening diseases,” said Cynata CEO Dr Kilian Kelly. “Heading into two major trials with that data behind us gives us a much higher degree of confidence than is typical at this stage of biotech development.”

Why Cynata is Different

 Traditional MSC manufacturing relies on collecting appropriate donor tissue, isolating MSCs, and then growing those cells in the lab (known as “culture expansion”). But MSCs are naturally scarce, and when they go through extensive culture expansion, their potency declines. That means therapies made from these donor-derived MSCs face problems of supply, consistency, and declining effectiveness.

Cynata’s Cymerus™ process bypasses all of that. By reprogramming cells originally derived from a single healthy donor into induced pluripotent stem cells (iPSCs) - effectively “master cells” - the company can generate MSCs over and over again, forever. Cynata’s process doesn’t start with the search for new donors – it starts with lifting a vial of high-quality iPSCs out of the freezer. The result is a stable, scalable, pharmaceutical-grade source of regenerative cells ready for off-the-shelf use across multiple diseases

It’s a manufacturing breakthrough that gives Cynata a commanding position in a fast-maturing field. More than 1,800 MSC clinical trials have been initiated worldwide, but few have reached late-stage development. Cynata is now the first company worldwide to see a Phase 3 program using iPSC-derived MSCs come to conclusion- an achievement that could set a new global benchmark for the field.

Why Cynata should be on your watchlist

Cynata’s pipeline is focused on high-value indications where inflammation and immune dysfunction play central roles. The company’s two most advanced programs - Osteoarthritis (CYP-004) and Acute Graft-versus-Host Disease (aGvHD, CYP-001) - are both nearing major data readouts in the coming 6–9 months.

Its Phase 3 osteoarthritis trial, led by the University of Sydney and funded by the NHMRC, is investigating whether Cymerus™ MSCs can relieve knee pain, improve mobility, and slow cartilage loss - outcomes that could transform treatment for more than 600 million people worldwide who currently have no disease-modifying option.

Meanwhile, the company’s Phase 2 aGvHD trial represents another major inflection point. Acute GvHD is a life-threatening complication of bone marrow transplants, where the donor’s immune cells attack the recipient’s tissues. First line steroid treatments fail in about half of cases, leaving survival rates as low as 20% after two years.

Cynata’s earlier Phase 1 clinical trial in humans provided compelling evidence that it could address this need. In patients with severe, steroid-resistant aGvHD, 87% improved by at least one grade, 53% achieved complete resolution of disease, and 60% were still alive two years later, with no serious treatment-related adverse events. The successful outcomes of this trial were published in two articles in a world-leading scientific journal Nature Medicine.

For investors, this prior in-human efficacy data represents a potential de-risking factor. Most biotechnology companies enter trials without clear evidence that their therapy works in humans, meaning the probability of success - and therefore valuation — is much lower. Cynata’s data gives it a rare advantage: it already knows its cells can achieve clinical benefit and do so safely. In a sector where proof of human efficacy is often the difference between speculation and validation, Cynata stands out as one of the few biotechs entering a pivotal trial with real-world evidence already in hand.

“Being only 6–9 months away from two major clinical trial readouts places Cynata in an exciting position,” Dr Kelly said. “While there is never zero risk in clinical trials, heading into these results with excellent efficacy results obtained in Cynata’s phase 1 clinical trials in steroid-resistant aGvHD and diabetic foot ulcers is a great advantage.”

In a bold pivot towards the bleeding edge of neuro-oncology diagnostics, Perth-based TrivarX (ASX: TRI) has inked a deal to acquire the intellectual property behind a novel brain imaging platform, Stabl-Im™, from biotech outfit Nucleics Pty Ltd. The technology, which promises to detect brain tumours earlier and more safely than current MRI methods, could be a genuine game-changer in the clinical management of brain metastases - a condition that afflicts up to one in five adult cancer patients.

The Stabl-Im platform uses stable isotope labelling to flag replicating cells — a biological hallmark of tumour growth absent in healthy adult brain tissue. The kicker? It can be visualised using standard MRI equipment, meaning no radioactive tracers or invasive biopsies. This is particularly significant, given current MRI-based surveillance can only detect tumours once they've reached 2-3mm in size, often too late for meaningful intervention.

As TrivarX Chairman David Trimboli put it: “This transaction marks an important evolution for TrivarX, firmly strengthening our position in the neurological diagnostics sector, while providing exposure to the fast-growing brain cancer imaging market.”

Trimboli's optimism isn’t just PR fluff. The global neuro-oncology diagnostics market is tipped to hit US$2.5 billion by 2030, and the brain metastases treatment segment could balloon to US$8.8 billion by 2035. In a field where survival is measured in weeks post-diagnosis, the ability to detect tumours earlier - and more safely - could materially change patient outcomes.

Dr Daniel Tillett

Backing the science is biotech heavyweight Dr Daniel Tillett, founder and CEO of Nucleics and also the Managing Director of Race Oncology (ASX: RAC). Dr Tillett isn't just licensing out his IP; he’s cornerstoning a $4.2 million placement with a $500,000 personal investment. That kind of skin in the game rarely goes unnoticed in biotech circles.

“We developed the Stabl-Im IP with the vision to transform how clinicians can detect and monitor metastatic brain tumours - safely, non-invasively, and earlier than ever before,” said Dr Tillett. “TrivarX's experience and commitment to diagnostics and precision neuro-medicine make them the ideal partner.”

The $4.2 million placement, priced at $0.008 per share - a 30% discount to the 15-day VWAP - will fund the transaction and accelerate clinical development. Directors have also thrown in $200,000 (subject to shareholder approval), adding a further layer of conviction. The capital raise is structured in two tranches, with Perth-based JP Equity Partners taking the lead manager role.

Clinical work is scheduled to begin in earnest, with manufacturing and regulatory pre-submissions planned for the US and EU. A Phase 1 trial, aimed at assessing safety and imaging precision, is pencilled in for calendar year 2026. If successful, performance milestones will trigger the issue of up to 750 million shares a significant kicker for Nucleics, tied to trial outcomes.

Importantly, TrivarX isn’t throwing the rest of its toolkit out with the petri dish. Stabl-Im complements its existing work in mental health diagnostics, including MEB-001 and its AI-powered ECG platform for detecting Major Depressive Episodes. With a foot firmly in both neurological and psychiatric territory, the company appears to be positioning itself as a diagnostics platform play - not just a one-trick biotech pony.

For a small-cap, TRI’s aspirations are big, and the backing of a figure like Dr Tillett lends the endeavour a degree of credibility. That said, the path from IP acquisition to clinical success is long, expensive, and littered with risk. But for investors keen on frontier medtech with global upside, this is one ticker worth watching - particularly as the Phase 1 trial looms.

The real test, as always, will be in the clinic. If Stabl-Im lives up to its billing, TrivarX could find itself not just diagnosing brain tumours earlier - but rewriting the rules of engagement for neuro-oncology altogether.

Adisyn Limited (ASX: AI1) has been spotlighted in a new Pitt Street Research report for its pioneering work developing graphene-based interconnects designed to overcome the physical and performance limits of copper in advanced computer chips.

The research note, “Solving a Major Semiconductor Bottleneck,” released on 16 October 2025, reaffirms a valuation of A$0.29 per share, with analysts saying Adisyn’s breakthrough could help sustain Moore’s Law by enabling faster, smaller, and more energy-efficient semiconductor design.

Copper’s Limits Spark Graphene Race

As transistors in integrated circuits shrink below 10 nanometres, the copper interconnects that link them face rapidly increasing resistivity, energy loss, and overheating. This has created a major technological bottleneck for chipmakers trying to advance to sub-5nm nodes.

Adisyn’s wholly owned subsidiary 2D Generation is at the forefront of solving this issue through its low-temperature Atomic Layer Deposition (ALD) graphene technology, which enables high-quality graphene growth at temperatures compatible with existing semiconductor manufacturing.

“Graphene interconnects can deliver faster signal transmission, reduced power consumption, and lower heat generation — three of the biggest challenges facing next-generation chip design,” the Pitt Street Research report notes.

Dual ALD Systems Accelerate Research Progress

According to the company’s August 2025 R&D update, Adisyn has now commissioned two Beneq TFS 200 ALD systems - one installed at its Israeli R&D centre and another leased through Tel Aviv University’s Nano Center.

Beneq TFS 200 ALD system

These systems allow Adisyn’s team to test multiple precursors and reaction conditions simultaneously, advancing the refinement of its proprietary graphene deposition “recipe.” The company’s Phase One program, now underway, is focused on precursor testing, plasma cleaning, graphene growth, annealing, and continuous optimisation - all aimed at validating repeatability and scalability.

This research will continue through early 2026, culminating in the production of a Demo Prototype to prove that graphene can outperform copper in semiconductor applications.

Strong Team and Global Research Collaborations

Pitt Street Research’s report emphasises the calibre of Adisyn’s international leadership and partnerships as a key differentiator.

The graphene development program is led by semiconductor veteran Kevin Crofton (former Lam Research and SPTS Technologies CEO), Arye Kohavi (founder of Water-Gen), and Miri Kish Dagan, one of Israel’s leading R&D executives.

Adisyn is collaborating with some of the most respected institutions and programs in global semiconductor research, including:

• imec (Belgium), for simulation and validation of graphene deposition processes;

• Tel Aviv University, for advanced characterisation and ALD access; and

• ConnectingChips, an EU-led consortium involving NVIDIA, NXP, Applied Materials, and Valeo, under the EU Chips Act initiative.

A Trillion-Dollar Opportunity

The Pitt Street Research analysis places Adisyn’s work within a booming global semiconductor market projected to exceed US$1 trillion by 2030, up from US$600 billion today.

As artificial intelligence, data centres, and 6G communications demand increasingly powerful chips, materials like graphene could become essential to maintaining performance gains and efficiency improvements.

“Adisyn’s low-temperature graphene ALD process could be the enabling technology that allows sub-2nm chip production,” the report concludes, adding that success could “trigger M&A interest from major equipment manufacturers such as Lam Research, ASM International, or Applied Materials”.

Valuation and Upcoming Milestones

Pitt Street Research reaffirmed its A$0.29 per share valuation, composed of A$0.22 for 2D Generation and A$0.07 for Adisyn’s legacy IT services business, and identified several upcoming catalysts for investors:

• Ongoing graphene deposition progress reports;

• imec and ConnectingChips collaboration updates;

• Delivery of the 2026 Demo Prototype; and

• Potential commercial partnerships or licensing opportunities.

Redefining Semiconductor Innovation

By addressing one of the semiconductor industry’s most persistent engineering limits, Adisyn’s research could mark a pivotal moment for global chip design.

As Pitt Street Research notes, “If Adisyn succeeds in demonstrating a full proof of concept, it will have solved a fundamental bottleneck in the chip industry.”

With two operational ALD systems, high-level global partnerships, and a clear technical roadmap toward a 2026 prototype, Adisyn’s graphene interconnect program is positioning the ASX-listed company at the forefront of the next generation of semiconductor innovation.

To access the full research report click HERE

Australian hearing health innovator Audeara (ASX: AUA) has taken a meaningful step into the booming Chinese medical device market, announcing its first purchase order under a licensing deal with Eastech (Huizhou) Co., Ltd., a subsidiary of Taiwan-listed Eastech Holding (TWSE: 5225).

This order marks the commercial debut of Audeara’s proprietary hearing aid technology in China, a market with an estimated 426 million people affected by hearing loss—a number projected to balloon to 561 million by 2034, or around 40% of the population.

While modest in volume - just 1,000 licence keys - the order represents a foothold in a region that could reshape the company's revenue profile in the years ahead. As CEO and Managing Director Dr James Fielding put it:

“Securing this first order is a significant milestone for Audeara. It demonstrates the commercial traction of our technology and the strength of our collaboration with Eastech in bringing personalised hearing solutions to one of the largest healthcare markets in the world.

Dr James Fielding

Deal Mechanics: Eastech, E-commerce, and Earbuds

The agreement, first unveiled in August, gives Eastech access to Audeara’s proprietary hearing enhancement technology and engineering know-how, to be used in the development of hearing devices certified by China’s National Medical Products Administration (NMPA).

In turn, the final products will be distributed under a third-party brand, leveraging China’s formidable e-commerce ecosystem. Sales channels include Tmall, JD.com, and Pinduoduo - platforms that collectively cater to hundreds of millions of shoppers.

Importantly, Audeara doesn’t bear the burden of local certification or consumer distribution. That heavy lifting falls to Eastech and its Chinese distribution partner, allowing Audeara to focus on what it does best: refining and licensing its tech.

Dollars and Decibels

Financially, Audeara will receive royalties per unit sold, though the initial order is not considered material in isolation. There are no minimum purchase commitments, meaning future revenue will hinge on product uptake rather than locked-in sales targets.

That may temper short-term excitement from investors looking for immediate windfalls. But the structure does position the company to scale quickly if the products resonate (pardon the pun) with Chinese consumers.

Market Potential: Not Just Noise

Let’s not downplay the scale here. China’s hearing health market is both underserved and accelerating, thanks to demographic tailwinds from an ageing population and rising health awareness. The World Health Organization has pegged untreated hearing loss as a significant public health issue across Asia-Pacific.

For Audeara, it’s also about strategic diversification. Until now, the Brisbane-based firm has focused primarily on developed Western markets, selling its hearing-optimised audio products through audiology clinics, NDIS providers, and direct-to-consumer e-commerce. This Chinese push represents not just expansion, but evolution - from hardware maker to licensor of proprietary health tech IP.

And the company isn’t going it alone. Eastech brings credibility, scale, and experience in advanced electronics, with a market capitalisation of over A$350 million and a background in both consumer and medical devices.

Sound Strategy or White Noise?

While the initial numbers are small, the partnership gives Audeara exposure to the world’s largest addressable market for hearing loss - without the need to build boots-on-the-ground infrastructure.

Assuming the product launch, targeted for Q4 2025, finds favour with Chinese consumers, subsequent orders could bring material revenue uplift. Investors will be watching for updates on unit volumes, customer adoption, and eventual royalty streams.

As Dr Fielding noted:

“Our technology is now being released to Eastech, ahead of production and a broader launch later this year. We look forward to providing additional updates on developments in the coming months.

For now, the real story is not in the quantity of licence keys, but in the door they unlock. Whether Audeara can amplify this early success into a chorus of commercial orders remains to be heard - but the pitch is promising.

Clarity Pharmaceuticals (ASX:CU6), a clinical-stage radiopharmaceutical company developing next-generation cancer diagnostics and therapies, has announced that its Co-PSMA Phase II trial has met its primary endpoint. The investigator-initiated trial demonstrated statistically significant superiority of Clarity’s proprietary 64Cu-SAR-bisPSMA diagnostic over the current standard of care, 68Ga-PSMA-11 PET/CT, for detecting prostate cancer recurrence in patients with low PSA levels.

Led by Prof Louise Emmett at St Vincent’s Hospital in Sydney, the trial showed that 64Cu-SAR-bisPSMA PET/CT detected a greater number of prostate-specific membrane antigen (PSMA)-positive lesions in patients post-radical prostatectomy with biochemical recurrence, a setting where early detection is crucial for guiding salvage therapy.

Executive Chairperson Dr Alan Taylor said the result is a significant validation of Clarity’s proprietary SAR Technology Platform and strengthens the case for 64Cu-SAR-bisPSMA as a potential new standard in PSMA imaging.

“Achieving the primary endpoint in the Co-PSMA trial, in direct comparison to a standard-of-care agent, further validates 64Cu-SAR-bisPSMA as a best-in-class diagnostic. With two Fast Track Designations and Phase III trials underway, we are well positioned to commercialise a superior tool for the early detection of prostate cancer recurrence,” Dr Taylor said.

Raising the Bar in Prostate Cancer Imaging

The Co-PSMA results follow promising data from Clarity’s COBRA and PROPELLER trials, which also demonstrated higher detection rates using 64Cu-SAR-bisPSMA. In COBRA, the agent identified twice as many lesions as SOC imaging in some settings and offered lesion detection up to six months earlier than conventional methods. PROPELLER, meanwhile, confirmed increased tumour uptake and superior image contrast on same-day scans.

Clarity’s 64Cu-based agent offers both diagnostic and therapeutic applications when combined with copper-67—a theranostic pairing that leverages the company’s proprietary SAR chelator technology to prevent free copper leakage and enable same-day and next-day imaging without degradation.

Importantly, 64Cu-SAR-bisPSMA enables detection of very small lesions—down to 2 mm—helping to capture cancer recurrence in its earliest stages. This can be particularly impactful in men with low PSA levels, where standard imaging agents often lack the required sensitivity.

Commercial Implications and Market Opportunity

Clarity estimates the current US market for PSMA PET imaging is around US$2 billion annually, with projections pointing to over US$3 billion by 2029. Yet this market is still dominated by low-sensitivity agents, including 68Ga-PSMA-11, which is unpatented and being commercialised by multiple groups.

With a proprietary, high-sensitivity product and robust clinical data, Clarity believes it is well positioned not only to capture market share but to expand the diagnostic opportunity by enabling earlier intervention.

The company is progressing registrational Phase III trials—AMPLIFY and CLARIFY—in support of FDA New Drug Applications (NDAs), targeting regulatory approvals and commercial rollout in the US and global markets.

As prostate cancer remains the second most diagnosed cancer in men worldwide, and a leading cause of cancer death, the need for earlier and more accurate imaging tools is pressing. Clarity’s latest clinical milestone brings it a step closer to redefining the diagnostic landscape.